TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9343033

Group type: EXPERIMENTAL
Intervention: Oral propafenone (600 mg loading dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8201510

Group type: EXPERIMENTAL
Intervention: Modified bovine lung surfactant extract (beractant), 4 doses
Number of subjects: 17

Group type: COMPARATOR
Intervention: Air (control group), equal volume to surfactant group
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: CDH infants
Number of subjects: 17
Study: 2906778

Group type: EXPERIMENTAL
Intervention: Lormetazepam (sublingual administration)
Number of subjects: 48
Study: 28972663

Group type: EXPERIMENTAL
Intervention: Daylight photodynamic therapy (DLPDT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional photodynamic therapy (CPDT)
Number of subjects: 46
Study: 27547851

Group type: EXPERIMENTAL
Intervention: G1 (twice a week plyometric training)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: G2 (twice a week plyometric training)
Number of subjects: 16

Group type: COMPARATOR
Intervention: G1 and G2
Number of subjects: 16
Study: 25062570

Group type: EXPERIMENTAL
Intervention: Early oral nutritional supplements
Number of subjects: 46

Group type: COMPARATOR
Intervention: Traditional treatment with water or lemonade
Number of subjects: 46
Study: 23739438

Group type: EXPERIMENTAL
Intervention: mydocalm
Number of subjects: 1700

Group type: COMPARATOR
Intervention: control group (no mydocalm)
Number of subjects: 1700
Study: 20004758

Group type: COMPARATOR
Intervention: Exercise 0 days/week
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Exercise 2 days/week
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Exercise 4 days/week
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Exercise 7 days/week
Number of subjects: 61
Study: 18225981

Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Number of subjects: 547

Group type: COMPARATOR
Intervention: Vancomycin plus ceftazidime
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Ceftobiprole and Vancomycin plus ceftazidime
Number of subjects: 547
Study: 16625281

Group type: EXPERIMENTAL
Intervention: Chronic bacterial prostatitis (CBPP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Healthy adult volunteers (HAV)
Number of subjects: 70
Study: 14659774

Group type: EXPERIMENTAL
Intervention: Cholesterol/HDL-cholesterol (CHOL/HDL) in CAD patients
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Triglycerides (TG) in CAD patients
Number of subjects: 71
Study: 10904184

Group type: EXPERIMENTAL
Intervention: Tea prepared from leaves of S. cumini
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Crude extract prepared from leaves of S. cumini
Number of subjects: 30
Study: 8737000

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1572759

Group type: EXPERIMENTAL
Intervention: Test A
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Test B
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Test C
Number of subjects: 18
Study: 3912186

Group type: EXPERIMENTAL
Intervention: Bambuterol 30 mg administered once daily before going to bed
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sustained release terbutaline 10 mg twice daily
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Bambuterol 30 mg administered once daily
Number of subjects: 27
Study: 31145150

Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 0
Study: 29144535

Group type: EXPERIMENTAL
Intervention: Guided internet‐ and mobile‐supported occupational stress‐management intervention (iSMI) consisting of seven sessions and one booster session
Number of subjects: 264

Group type: COMPARATOR
Intervention: Waitlist control (WLC) with unrestricted access to treatment as usual
Number of subjects: 264
Study: 27421672

Group type: EXPERIMENTAL
Intervention: Group A: intravenous administration of contrast material at a dose of 1mL/kg and CTA examinations at 100kV
Number of subjects: 101

Group type: COMPARATOR
Intervention: Group B: intravenous administration of contrast material at a dose of 0.5mL/kg and CTA examinations at 80kV
Number of subjects: 101
Study: 24045855

Group type: EXPERIMENTAL
Intervention: Protein drink containing 15 g protein, twice a day
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo drink, twice a day
Number of subjects: 65
Study: 21790634

Group type: EXPERIMENTAL
Intervention: RBC transfusion in symptomatic anemic premature neonates
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Baseline SCOR in symptomatic subjects who improved after transfusion
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Baseline SCOR in symptomatic subjects who did not improve after transfusion
Number of subjects: 52

Group type: COMPARATOR
Intervention: Baseline SCOR in asymptomatic neonates
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Low baseline SCOR (≤ 0.73) in symptomatic subjects
Number of subjects: 52
Study: 19326107

Group type: EXPERIMENTAL
Intervention: Probiotics/synbiotics
Number of subjects: 733
Study: 17998081

Group type: EXPERIMENTAL
Intervention: Prepaid monetary incentive
Number of subjects: 3825

Group type: EXPERIMENTAL
Intervention: Short questionnaire
Number of subjects: 3825

Group type: COMPARATOR
Intervention: Control group (no monetary incentive)
Number of subjects: 3825

Group type: COMPARATOR
Intervention: Control group (long questionnaire)
Number of subjects: 3825
Study: 15241753

Group type: EXPERIMENTAL
Intervention: Bilateral arm-based training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy participants)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (participants with hemiparesis)
Number of subjects: 20
Study: 12269645

Group type: EXPERIMENTAL
Intervention: Ebastine (20 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9636965

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL) cells from BOS patients
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: BOS patients
Number of subjects: 6

Group type: COMPARATOR
Intervention: Controls (unaffected recipients)
Number of subjects: 6
Study: 8206064

Group type: EXPERIMENTAL
Intervention: Single dose of piperacillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three doses of piperacillin
Number of subjects: 0
Study: 2687897

Group type: EXPERIMENTAL
Intervention: 600 mg bamyphylline
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29779220

Group type: EXPERIMENTAL
Intervention: Micrografts seeded onto collagen sponge (Test group, n=15)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Collagen sponge alone (Control group, n=14)
Number of subjects: 29
Study: 26053680

Group type: EXPERIMENTAL
Intervention: Metformin plus a hypocaloric diet for 6 months (group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment (group B)
Number of subjects: 20
Study: 26233620

Group type: EXPERIMENTAL
Intervention: Clarus Levitan fiberoptic stylet (FPS)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (MAC)
Number of subjects: 89
Study: 24041479

Group type: EXPERIMENTAL
Intervention: Psyfit intervention for 2 months
Number of subjects: 284

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 284
Study: 20095806

Group type: EXPERIMENTAL
Intervention: 500 mg glucocorticosteroids for 5 days
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 1000 mg glucocorticosteroids for 5 days
Number of subjects: 35
Study: 19029466

Group type: EXPERIMENTAL
Intervention: torcetrapib/atorvastatin
Number of subjects: 910

Group type: COMPARATOR
Intervention: atorvastatin monotherapy
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: torcetrapib
Number of subjects: 910
Study: 15737448

Group type: EXPERIMENTAL
Intervention: Unilateral lower-limb amputees
Number of subjects: 18

Group type: COMPARATOR
Intervention: Able-bodied controls
Number of subjects: 18
Study: 12633912

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 55
Study: 10880708

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 290
Study: 8893393

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Didanosine
Number of subjects: 12
Study: 1985164

Group type: EXPERIMENTAL
Intervention: Cranial radiation (1,800 cGy) and intrathecal methotrexate (RT group)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Parenteral methotrexate (MTX group)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Both RT and MTX groups
Number of subjects: 49
Study: 6849644

Group type: EXPERIMENTAL
Intervention: Amikacin sulfate (7.5 mg/kg, IM) - single dose
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Amikacin sulfate (7.5 mg/kg, IM) - two doses (5 1/2 to 12 hours apart)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Amikacin sulfate (7.5 mg/kg, IM) - second dose given 9 to 12 hours after first
Number of subjects: 73
Study: 31968080

Group type: EXPERIMENTAL
Intervention: High tidal volume (12 mL/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low tidal volume (6 mL/kg)
Number of subjects: 18
Study: 31274110

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 872
Study: 28892265

Group type: EXPERIMENTAL
Intervention: Flurbiprofen preemptive analgesia
Number of subjects: 89

Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 89

Group type: COMPARATOR
Intervention: Thoracoscopy and laparoscopic surgery
Number of subjects: 89
Study: 27147264

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761® (240 mg daily)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 25078578

Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis
Number of subjects: 8

Group type: COMPARATOR
Intervention: Superficial venous thrombolysis
Number of subjects: 8
Study: 23011014

Group type: EXPERIMENTAL
Intervention: Generic artemether/lumefantrine 20/120 mg tablets
Number of subjects: 0
Study: 19414437

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of ET‐A receptor blocker BQ‐123 (40 nmol/min, group A, n = 13)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of ET‐A receptor blocker BQ‐123 (40 nmol/min) and ET‐B receptor blocker BQ‐788 (10 nmol/min, group AB, n = 13)
Number of subjects: 26

Group type: COMPARATOR
Intervention: ET‐receptor blockade (both groups)
Number of subjects: 26
Study: 16388944

Group type: EXPERIMENTAL
Intervention: Hankison based FEV1/FVC interpretation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hankison based FEV1/FEV6 interpretation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Morris predictive equations for FEV1/FVC
Number of subjects: 100
Study: 12816266

Group type: EXPERIMENTAL
Intervention: Aprotinin (30,000 KIU/kg on induction and 10,000 KIU/kg/hr infusion until surgery completion, max 8 hours)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 100
Study: 11156281

Group type: EXPERIMENTAL
Intervention: Combined recovery (involving active and massage components)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Active recovery
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combined recovery
Number of subjects: 18

Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 18

Group type: COMPARATOR
Intervention: Massage recovery
Number of subjects: 18
Study: 8635612

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose (75IU) human menopausal gonadotrophin (hMG)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Pure FSH
Number of subjects: 164
Study: 1300037

Group type: EXPERIMENTAL
Intervention: 400 mg cimetidine (Cim)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 30 mg ranitidine (Ran)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6380485

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31892674

Group type: EXPERIMENTAL
Intervention: Topical agent with laser
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Topical agent only
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (placebo prescription)
Number of subjects: 50
Study: 29199720

Group type: EXPERIMENTAL
Intervention: Capecitabine (1650 mg/m2 on RT days throughout the course of radiotherapy)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 5FU (500 mg/m2 on RT days #1‐#5 and #21‐#25)
Number of subjects: 30
Study: 26341927

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (healthy age-matched)
Number of subjects: 60
Study: 24488721

Group type: EXPERIMENTAL
Intervention: Tideglusib 600 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Tideglusib 800 mg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 22167570

Group type: COMPARATOR
Intervention: Atorvastatin (1 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rosuvastatin (1 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simvastatin (1 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atorvastatin and simvastatin in healthy human subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosuvastatin in healthy human subjects
Number of subjects: 0
Study: 19079942

Group type: EXPERIMENTAL
Intervention: MUFA diet
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: LF diet
Number of subjects: 131

Group type: COMPARATOR
Intervention: CTR diet
Number of subjects: 131
Study: 17241782

Group type: EXPERIMENTAL
Intervention: BXL-628 (elocalcitol)
Number of subjects: 0
Study: 16189333

Group type: EXPERIMENTAL
Intervention: 30 mL of 0.5% bupivacaine with midazolam 50 microg x kg(‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 30 mL of 0.5% bupivacaine
Number of subjects: 40
Study: 14621278

Group type: EXPERIMENTAL
Intervention: Antisecretory factor (AF) treatment as an additive to conventional UC medication
Number of subjects: 20
Study: 10804075

Group type: EXPERIMENTAL
Intervention: Sertraline (up to 100 mg/day)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Nortriptyline (low vs. regular doses)
Number of subjects: 97
Study: 8796796

Group type: EXPERIMENTAL
Intervention: Exercise (upright stationary cycling for 30 min at 60% VO2max)
Number of subjects: 11
Study: 1298491

Group type: EXPERIMENTAL
Intervention: Tenoxicam 40 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Paracetamol 1,000 mg
Number of subjects: 30
Study: 6724670

Group type: EXPERIMENTAL
Intervention: Stepped Care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Referred Care
Number of subjects: 0
Study: 30591393

Group type: EXPERIMENTAL
Intervention: Repair of the orbicularis oris muscle and dissection of both origin and abnormal insertion of the nasalis muscle (Group 2B)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Repair of the orbicularis muscle only (Group 1)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Repair of the orbicularis oris muscle and dissection and repair the origin of the nasalis muscle (Subgroup A)
Number of subjects: 45
Study: 27422973

Group type: EXPERIMENTAL
Intervention: HPG/PEG/PG
Number of subjects: 94

Group type: COMPARATOR
Intervention: O/CMC
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 94
Study: 25362105

Group type: EXPERIMENTAL
Intervention: Increasing gait speed
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Increasing step length
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Increase in swing time at second follow-up (2.8±0.6 years)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Increase in double support phase at second follow-up (2.8±0.6 years)
Number of subjects: 135
Study: 24075226

Group type: EXPERIMENTAL
Intervention: Menthol cigarettes
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Caucasian menthol smokers
Number of subjects: 301

Group type: COMPARATOR
Intervention: Smoking cessation
Number of subjects: 301
Study: 21307076

Group type: EXPERIMENTAL
Intervention: Nasal insulin
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 19822770

Group type: EXPERIMENTAL
Intervention: Serum urate concentration
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid urate concentration
Number of subjects: 800

Group type: COMPARATOR
Intervention: Subjects not treated with alpha‐tocopherol (2000 IU/d)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Subjects treated with alpha‐tocopherol (2000 IU/d)
Number of subjects: 800
Study: 17166393

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 0
Study: 15288319

Group type: EXPERIMENTAL
Intervention: Azithromycin (3-day course)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Other antibiotics (10-day course)
Number of subjects: 108
Study: 11402407

Group type: EXPERIMENTAL
Intervention: Subvastus approach (group II)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standard medial parapatellar arthrotomy (group I)
Number of subjects: 89
Study: 9007457

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8479715

Group type: EXPERIMENTAL
Intervention: Eye muscle reflectivity measurement in patients with Graves ophthalmopathy
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Eye muscle reflectivity measurement in responders to treatment
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cut-off value of 40% for eye muscle reflectivity
Number of subjects: 16
Study: 3317344

Group type: EXPERIMENTAL
Intervention: Yeast-derived hepatitis B vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plasma-derived hepatitis B vaccine (20 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partly purified recombinant vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant vaccine
Number of subjects: 0
Study: 31070807

Group type: EXPERIMENTAL
Intervention: Hierarchical EMAX model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EMAX model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Independent model
Number of subjects: 0
Study: 30479829

Group type: EXPERIMENTAL
Intervention: e-learning resource co-produced with African-Caribbean stakeholders
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 27191766

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 6990

Group type: EXPERIMENTAL
Intervention: Ticagrelor with moderate CYP3A inducers
Number of subjects: 6990

Group type: EXPERIMENTAL
Intervention: Ticagrelor with moderate CYP3A inhibitors
Number of subjects: 6990

Group type: EXPERIMENTAL
Intervention: Ticagrelor in habitual smokers
Number of subjects: 6990

Group type: EXPERIMENTAL
Intervention: Ticagrelor at treatment initiation (visit 1)
Number of subjects: 6990

Group type: EXPERIMENTAL
Intervention: Ticagrelor in Asian patients
Number of subjects: 6990

Group type: EXPERIMENTAL
Intervention: Ticagrelor in Black patients
Number of subjects: 6990
Study: 25038293

Group type: EXPERIMENTAL
Intervention: Online psychoeducation intervention (n=33)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Online attention-matched control information (n=34)
Number of subjects: 67
Study: 22127409

Group type: EXPERIMENTAL
Intervention: Holmium laser endourethrotomy (HLU)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Optical internal urethrotomy (OIU)
Number of subjects: 50
Study: 19803607

Group type: EXPERIMENTAL
Intervention: Adolescents with PTSD
Number of subjects: 144

Group type: COMPARATOR
Intervention: Adolescents without PTSD
Number of subjects: 144

Group type: COMPARATOR
Intervention: Mothers
Number of subjects: 144

Group type: COMPARATOR
Intervention: Fathers
Number of subjects: 144
Study: 17609248

Group type: EXPERIMENTAL
Intervention: Remifentanil step‐up/‐down effect‐compartment target‐controlled infusion (Ce(remi)) of 0, 2, 6, 2, 0 ng ml(‐1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Remifentanil step‐up/‐down effect‐compartment target‐controlled infusion (Ce(remi)) of 6, 2, 0, 2, 6 ng ml(‐1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Noxious stimulus
Number of subjects: 40
Study: 15621318

Group type: EXPERIMENTAL
Intervention: Ultrasound indentation method
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group of healthy, non‐irradiated subjects
Number of subjects: 105
Study: 12192713

Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) administration of diluted injectable quinimax at a dose of 12.5 mg/kg every 12 hours for 72 hours.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Intrarectal (IR) administration of diluted injectable quinimax at a dose of 15 mg/kg every 12 hours for 72 hours.
Number of subjects: 64
Study: 9824925

Group type: EXPERIMENTAL
Intervention: Peer in a wheelchair (SAQ‐Self)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Peer in a wheelchair (SAQ‐Others)
Number of subjects: 120
Study: 8130028

Group type: EXPERIMENTAL
Intervention: Allopurinol (1200 mg in two divided doses)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 2528306

Group type: EXPERIMENTAL
Intervention: Mivacurium bolus dose 0.15 mg/kg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Mivacurium bolus dose 0.25 mg/kg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Mivacurium bolus dose (both 0.15 mg/kg and 0.25 mg/kg) with no additional mivacurium
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Mivacurium infusion adjusted to depress twitch response by approximately 95%
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Mivacurium infusion rates
Number of subjects: 72

Group type: COMPARATOR
Intervention: Anesthetic technique (balanced vs enflurane)
Number of subjects: 72
Study: 1161344

Group type: EXPERIMENTAL
Intervention: Group A (oral sodium bicarbonate treatment when base excess > -8 mEq/liter or suspected acidosis)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Group B (oral sodium bicarbonate treatment maintaining base excess within 1 SD of normal)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Group A (oral sodium bicarbonate treatment)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Group B (oral sodium bicarbonate treatment)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: SGA infants
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: AGA infants
Number of subjects: 26